Abstract
Despite advances in chronic heart failure (CHF) medical and device therapy in recent years, CHF continues to be a syndrome associated with significant morbidity and mortality. Abundance of data suggests that anemia is prevalent in CHF. The pathophysiology of CHF-related anemia is complex and poorly understood. Earlier small trials demonstrated improvement in morbidity with use of erythropoietin stimulating agents (ESA) and parenteral iron but that was not supported by more recent large randomized trials. There is a concern regarding the safety of ESA. Small studies showed benefits from parenteral iron alone or combination with ESA. This was promising since parenteral iron is a relatively cheap therapeutic intervention to treat anemia in CHF patients. So far there are no clear recommendations regarding the treatment of CHF related anemia. The purpose of this article is to review the most recent epidemiology, pathophysiology, and therapeutic options for anemia in CHF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Ibnosina Journal of Medicine and Biomedical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
